Emcure Pharmaceuticals Ltd.

“Emcure's India gynecology franchise is a durable, physician-relationship-driven moat in a structurally growing market, but it is surrounded by value-dilutive international generics, an active CBI investigation against the CMD, an ED/PMLA proceeding against the MD, and a Heritage Pharmaceuticals DOJ antitrust exposure — none of which are priced into a stock trading at 35.7x trailing and 26.5x forward earnings near its 52-week high. The long-term return potential of 2–2.5x over a decade is approximately market-rate for above-average governance risk, making this a poor risk-adjusted investment regardless of the India pharma structural tailwind.”